Trials / Completed
CompletedNCT00924248
Primovist Regulatory Post Marketing Surveillance (PMS)
Primovist Regulatory Post Marketing Surveillance
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 4,358 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The objective of this Post Marketing Surveillance (PMS) is to gain information about safety and efficacy in real practice
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gadoxetic acid disodium (Primovist, BAY86-4873) | Patients in daily life clinical practice treatment receiving Primovist according to indication on the label. |
Timeline
- Start date
- 2007-10-01
- Completion
- 2011-05-01
- First posted
- 2009-06-18
- Last updated
- 2012-09-19
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00924248. Inclusion in this directory is not an endorsement.